Ignite Creation Date:
2024-05-05 @ 11:38 PM
Last Modification Date:
2024-10-26 @ 10:37 AM
Study NCT ID:
NCT01380054
Status:
COMPLETED
Last Update Posted:
2021-09-05
First Post:
2011-06-06
Brief Title:
Pulmonary Hypertension Quality of Life and Psychosocial Factors
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Pulmonary Hypertension Impact of the Evolution of a Rare Disease on the Quality of Life and Role of Variables Psychosocial as Predictive of the Current and Later Quality of Life
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HyPsy
Brief Summary:
The investigators aim to
describe and analyse psychological characteristics cognitive factors and representations in patients with Pulmonary Hypertension a rare disease
assess the psychological characteristics impact on quality of life check the association between disease and QoL evolution and the variability of QoL parameters over severity class changes and follow-up
describe and analyse psychological characteristics cognitive factors and representations in patients with Pulmonary Hypertension a rare disease
assess the psychological characteristics impact on quality of life check the association between disease and QoL evolution and the variability of QoL parameters over severity class changes and follow-up
Detailed Description:
PAH is a rare and severe disease potentially mortal affecting preferentially young subjects The knowledge and the international literature as regards the quality of life the expectations the needs and the psychosocial characteristics of patients with PAH are non-existent But it is known that the persons affected by rare diseases are more vulnerable on the psychological social economic and cultural planIn all the stages of the treatment patients with PAH are confronted with heavy psychosocial situations in a context of vital risk with exceptional medicinal treatments intravenous administration at home
QoL might be differently affected by these changes according to situational and dispositional psychological dimensions
the predictive role of these characteristics on the current and later quality of life as well as the impact of diverse cognitive mediators and strategies to cope with the disease should be investigatedThe respiratory diseases department of the Montpellier hospital is regional competence center for PAH in Languedoc-Roussillon under the aegis of the national reference center the respiratory diseases department of Antoine Béclère hospital Le Petit-Clamart
QoL might be differently affected by these changes according to situational and dispositional psychological dimensions
the predictive role of these characteristics on the current and later quality of life as well as the impact of diverse cognitive mediators and strategies to cope with the disease should be investigatedThe respiratory diseases department of the Montpellier hospital is regional competence center for PAH in Languedoc-Roussillon under the aegis of the national reference center the respiratory diseases department of Antoine Béclère hospital Le Petit-Clamart
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-A00174-37 | OTHER | AFSSAPS | None |